Navigation Links
CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation
Date:4/15/2011

ATLANTA and IRVINE, Calif., April 15, 2011 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, today announced it has amended its tender offer related to its proposed acquisition of Cardiogenesis Corporation ("Cardiogenesis") to acquire only 49.9 percent of the outstanding shares of Cardiogenesis.  

On April 14, 2011, Cardiogenesis, CryoLife and CryoLife's wholly-owned subsidiary, CL Falcon, Inc., entered into an Amended and Restated Merger Agreement ("Agreement").  Pursuant to the Agreement, the tender offer has been revised to provide that CL Falcon, Inc. is offering to acquire only 49.9 percent of the outstanding shares of Cardiogenesis' common stock.  If more than 49.9 percent of the outstanding shares are tendered, CL Falcon, Inc. will purchase shares from the tendering shareholders on a prorated basis, as described in tender offer documents filed with the Securities and Exchange Commission ("SEC").  As a result of the Agreement, the Top-Up Option has been removed from the terms of the Offer and will no longer be effective.  The tender offer remains scheduled to expire at 12:00 midnight (one minute after 11:59 p.m.), New York City time, on the evening of May 2, 2011, unless extended.

Assuming that CryoLife acquires 49.9 percent of the outstanding shares of Cardiogenesis in the tender offer, Cardiogenesis will hold a special meeting of Cardiogenesis shareholders as soon as practical after the completion of the tender offer to vote on the proposed merger.  If more than 50 percent of the outstanding shares of Cardiogenesis, including those shares acquired by CryoLife in the tender offer, vote in favor of the merger, CryoLife and Cardiogenesis will move to complete the merger as soon as possible after the special meeting of Cardiogenesis shareholders.  Assu
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S.
2. David P. Lang Appointed Vice President of CryoLife International, Inc.
3. CryoLife to Present at UBS Global Life Sciences Conference
4. CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves
5. CryoLife to Present at UBS Global Life Sciences Conference
6. CryoLife Announces First Clinical Use of BioFoam(R)
7. CryoLifes Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
8. CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
9. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
10. CryoLife Reports Record First Quarter Revenues of $26.7 Million
11. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis plc ... pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced ... acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which ... the treatment of diabetic gastroparesis and other GI functional ... Phase 2 trial of relamorelin for the treatment of ...
(Date:10/22/2014)... NJ (PRWEB) October 22, 2014 ... and services – has been working with a team ... and New Haven Farms Community Farming Collaborative to provide ... ePRO solution. The study, which started in May, ... program that provides participants weekly exposure to and participation ...
(Date:10/22/2014)... Md. , Oct. 22, 2014   Synthetic ... developing novel pathogen-specific therapies for serious infections and diseases, ... has issued a Notice of Allowance for a composition ... its C. difficile program, SYN-004. This is ... SYN-004 in the U.S. and adds to the Company,s ...
(Date:10/20/2014)... 2014 The report “Pharmacy Automation ... Packaging and Labeling Systems, Table-top Counters) by End-user ... Forecasts & Trends to 2019” analyzes and studies ... North America, Europe, Asia-Pacific, and the Rest of ... and 30 figures spread through 300 pages and ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... Oct. 16 Compendia Bioscience, Inc.,today announced ... Premium Edition, a high-value product extension of ... Oncomine Research,Premium Edition includes custom gene filters, ... support for Oncomine Concepts Map,including the ability ...
... DRRX ) announced today that it will be hosting ... at 12:00 p.m. Eastern Time. A live audio,webcast of ... and will,be available by accessing DURECT,s homepage at ... to participate during the,live webcast, the call will be ...
... will receive milestones and ... by Altair - Altair to conduct clinical development ... FRANCISCO, Oct. 16 ,Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) ... Inc., a new venture,capital-funded biotechnology company, has been created to ...
Cached Biology Technology:Compendia Bioscience Announces the Release and Availability of Oncomine(TM) Research Premium Edition 2Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 2Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 3Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 4Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 5
(Date:10/15/2014)... Rosenstiel Award for Distinguished Work in Biomedical Science by ... of genomic instability and its implications for the immune ... to win the Rosenstiel Award; the first, Rod McKinnon, ... the Charles A. Janeway Professor of Pediatrics and Professor ... at the Howard Hughes Medical Institute at Boston Children,s ...
(Date:10/14/2014)... Research shows SIRT6—a protein known to inhibit the ... of skin cancers by turning on an enzyme that ... , Previously considered protective, SIRT6 is part of a ... genomic stability and prevent some of the genetic flaws ... can lead to cancer. This study, in the journal,s ...
(Date:10/14/2014)... leading questions is how to produce enough food to ... Food and Agriculture Organization of the United Nations predicts ... 40 years to feed a growing global population, and ... in food production. Plants—grains, cereals, fruits, vegetables, and ... Current research must tap into our knowledge of how ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... members gather at a picnic in your backyard, there may be ... When flies visit your party, be glad they don,t bring ... those are just the ones we know about. An Iowa ... have recently researched the fly family tree -- one of the ...
... dead sea bottoms to life. This creates the necessary ... nature itself to deal with eutrophication. By conducting pilot ... University of Gothenburg have demonstrated that pumping oxygen-rich surface ... wind-driven pump is now to be tested in open ...
... Harris, professor in the University of Minnesota,s College of Biological ... the National Institutes of Health to direct a large-scale research ... treating HIV and other viral diseases. The goal of ... the protein (APOBEC3G) to better understand how it interacts with ...
Cached Biology News:Too many relatives ruining your picnic? Be glad the flies don't invite their cousins 2Oxygenation at a depth of 120 meters can save the Baltic Sea 2U of M scientist gets 5-year, $10 million grant to direct innovative HIV research program 2
... a fluorescence scanner with 1 or 2 ... Protein, CGH, ) spotted on standard slides ... InnoScan700 scanners include three different models:, ... simultaneous dual fluorescence scanner (635nm and 532nm). ...
... Non-Radioactive Translation Detection Systems allow non-radioactive ... Using these systems, biotinylated lysine residues ... translation, eliminating the need for labeling ... acids. This biotinylated lysine is added ...
... Maximize the value of your microarray ... offer the support you need from ... the most up to date methods. ... the Gene Expression Profiling Service or ...
... your microarray data using Asuragens bioinformatics ... need from consultation to extensive data ... date methods. Utilize our expertise in ... Service or from your own microarray ...
Biology Products: